STEM:NASDAQ

StemCells Inc.

StemCells Inc. is engaged in the research and development of cell-based therapeutics. The company's proprietary HuCNS-SC cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. The company is currently conducting phase 1/2 clinical trials in chronic spinal cord injury and dry age-related macular degeneration. StemCells Inc. is also pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine. The company markets stem cell research products, including media and reagents, under the SC Proven brand.

Expert Comments:

Ching-Yi Lin, H.C. Wainwright & Co. (5/18/15)
"We are initiating StemCells Inc. with a Buy rating and using a discounted cash flow analysis to derive a price of $1. . .the two primary value drivers are treatment for dry age-related macular degeneration and chronic spinal cord injuries. Thus far, the preliminary data from these early trials are encouraging."

Jason Kolbert, Maxim Group (5/14/15)
"StemCells Inc. is presenting data at the American Spinal Injury Association meeting today. . .the data demonstrate safety. . .these data leave us encouraged that we may see even more robust results from the larger Phase 2 Pathway study which is now underway and rapidly enrolling."

Jason Kolbert, Maxim Group (5/6/15)
"StemCells Inc. closed financing in April, raising $23.5M or approximately $37.5M in cash on the balance sheet (enough capital to see critical results from dry age-related macular degeneration and even cohorts of the current spine trial, in our view). . .with capital raised and multiple data-driven catalysts, we believe 2015 is a year of inflection for the company."

Prashanth Vempa, Alpha Deal Group (4/21/15)
"An inflection point is coming soon for StemCells Inc. Patient transplants are to gallop in 2015 and 2016; the company has an attractive valuation now, and additional clinical data over the coming years provide catalysts for future stock appreciation."

Henry McCusker, Regenerative Medicine Investors (4/16/15)
"StemCells Inc. has completed transplanting the six patients comprising the first cohort of its Phase 2 Pathway study. . .the first controlled study to use neural stem cells with the intent to demonstrate improvement in motor function following spinal cord injury. The company expects to release six-month interim data on the first cohort later this year."

"StemCells Inc. is doing pioneering work in the field of cervical spinal cord Injury and dry age-related macular degeneration (dry AMD). The Pathway Phase 2 study is the first clinical trial designed to evaluate both the safety and efficacy of transplanting human neural stem cells into patients with cervical spinal cord injury, including traumatic injuries to the cervical region of the spinal cord. . .the primary endpoints will assess changes in patient upper extremity strength as measured in the hands, arms and shoulders. . .the other very exciting program is in dry AMD. Positive Phase 1/2 data using the HuCNS-SC platform in dry AMD was presented at the 12th annual meeting of the International Society for Stem Cell Research. . .interim trial results show a 65% reduction in the rate of geographic atrophy (GA) in the study eye. . .as well as a 70% reduction in the rate of GA when compared to the control eye. . .interim results also indicate improvements in visual function, as measured by the ability to distinguish shades of light versus dark. . .contrast sensitivity was improved in four of the seven patients, and remained stable in the other three patients. . .the Phase 2 study should begin in early 2015." read more >

More Expert Comments

Experts Commenting on This Company

Stephen Dunn
Jolene Furdek
Katherine Genis
Christopher James
Jason Kolbert
Ching-Yi Lin
Henry McCusker
Keay Nakae

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
StemCells Inc. Content